[Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Ourania Tatsis reported an open-market sale of 1,500 shares of Common Stock. The transaction took place on July 2, 2026 at a price of $524.99 per share. The filing states that the sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025, indicating it was pre-scheduled. After this transaction, Dr. Tatsis directly holds 45,321 shares of Vertex Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 1,500 shares ($787,485)

Net Sell 1 txn

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Sold 1,500 shs ($787K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,500	$524.99	$787K

Holdings After Transaction: Common Stock — 45,321 shares (Direct, null)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 04:16 PM Accepted by SEC EDGAR 07/07/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did VRTX executive Ourania Tatsis report?

EVP and Chief Regulatory & Quality Officer Ourania Tatsis reported selling 1,500 shares of Vertex common stock. The shares were sold in an open-market transaction on July 2, 2026, under a pre-established Rule 10b5-1 trading plan approved by the company.

How many VRTX shares did Ourania Tatsis sell and at what price?

She sold 1,500 shares of Vertex common stock at a price of $524.99 per share. The transaction was classified as an open-market sale and is identified with transaction code “S” in the Form 4 insider trading report.

How many VRTX shares does Ourania Tatsis hold after this sale?

Following the reported sale, Dr. Tatsis directly holds 45,321 shares of Vertex common stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects her remaining direct stake after the 1,500-share disposition.

Was the VRTX stock sale by Ourania Tatsis under a Rule 10b5-1 plan?

Yes. A footnote explains the transaction was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1. The plan was entered into on August 21, 2025, indicating the sale was pre-arranged rather than a discretionary market-timing decision.

Does the VRTX Form 4 show any derivative security exercises by Ourania Tatsis?

No derivative security transactions are listed in this Form 4. The derivative summary section is empty and the transaction summary shows zero exercises, indicating this filing only reports a non-derivative common stock sale, not option or other derivative exercises.

What does transaction code "S" mean in the VRTX Form 4 for Ourania Tatsis?

Transaction code “S” indicates a sale of securities in an open-market or private transaction. In this case, it refers to Dr. Tatsis’ sale of 1,500 shares of Vertex common stock, executed at $524.99 per share on July 2, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		S(1)		1,500	D	$524.99	45,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)